Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2008 Filed Feb 20, 2008 23:31 UTC |
Patton Donald V JRSenior Vice President
|
Tax withholdingCommon shares without par value | 1,459 | $55.55 | $81,047.45 |
DisclosureSEC source: 0001104659-08-011840 · a4.xml · nonDerivative · entry 2 Patton Donald V JR · CIK 0001396490 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,309 Read SEC document |
| February 17, 2008 Filed Feb 20, 2008 23:31 UTC |
Szela Mary TSenior Vice President
|
Tax withholdingCommon shares without par value | 1,227 | $55.55 | $68,159.85 |
DisclosureSEC source: 0001104659-08-011841 · a4.xml · nonDerivative · entry 2 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,447 Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:26 UTC |
Chen Thomas FSenior Vice President
|
GrantOption (right to buy) · Derivative | 78,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011825 · a4.xml · derivative · entry 7 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,700 Underlying: common shares · 78,700 shares Expires 2018-02-14 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,234 on 02/15/2009, 26,233 on 02/15/2010, and 26,233 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:26 UTC |
Chen Thomas FSenior Vice President
|
GrantCommon shares without par value | 19,700 | $55.56 | $1,094,532.00 |
DisclosureSEC source: 0001104659-08-011825 · a4.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,770 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:26 UTC |
Fussell Stephen RSenior Vice President
|
GrantOption (right to buy) · Derivative | 78,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011826 · a4.xml · derivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,700 Underlying: Common shares · 78,700 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,234 on 02/15/2009, 26,233 on 02/15/2010, and 26,233 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:26 UTC |
Fussell Stephen RSenior Vice President
|
GrantCommon shares without par value | 19,700 | $55.56 | $1,094,532.00 |
DisclosureSEC source: 0001104659-08-011826 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,021 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:26 UTC |
Schumacher Laura JExecutive Vice President
|
GrantOption (right to buy) · Derivative | 110,500 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011827 · a4.xml · derivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,500 Underlying: Common shares · 110,500 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 36,834 on 02/15/2009, 36,833 on 02/15/2010, and 36,833 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:26 UTC |
Schumacher Laura JExecutive Vice President
|
GrantCommon shares without par value | 27,200 | $55.56 | $1,511,232.00 |
DisclosureSEC source: 0001104659-08-011827 · a4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,502 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:27 UTC |
ASHLEY RICHARD WExecutive Vice President
|
GrantCommon shares without par value | 46,000 | $55.56 | $2,555,760.00 |
DisclosureSEC source: 0001104659-08-011828 · a4.xml · nonDerivative · entry 1 ASHLEY RICHARD W · CIK 0001278570 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,430 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:27 UTC |
LIEPMANN HOLGER AExecutive Vice President
|
GrantOption (right to buy) · Derivative | 97,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011829 · a4.xml · derivative · entry 9 LIEPMANN HOLGER A · CIK 0001283517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,700 Underlying: common shares · 97,700 shares Expires 2018-02-14 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,567on 2/15/09, 32,567 on 2/15/10 and 32,566 on 2/15/11. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:27 UTC |
LIEPMANN HOLGER AExecutive Vice President
|
GrantCommon shares without par value | 24,100 | $55.56 | $1,338,996.00 |
DisclosureSEC source: 0001104659-08-011829 · a4.xml · nonDerivative · entry 1 LIEPMANN HOLGER A · CIK 0001283517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,811 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The awards have a 5 year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GrantOption (right to buy) · Derivative | 530,000 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011830 · a4.xml · derivative · entry 7 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,000 Underlying: common shares · 530,000 shares Expires 2018-02-14 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 176,667on 2/15/09, 176,667 on 2/15/10 and 176,666 on 2/15/11. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GrantCommon shares without par value | 135,000 | $55.56 | $7,500,600.00 |
DisclosureSEC source: 0001104659-08-011830 · a4.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,172,800 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The awards have a 5 year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC |
Michael Edward L.Executive Vice President
|
GrantOption (right to buy) · Derivative | 93,400 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011831 · a4.xml · derivative · entry 6 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,400 Underlying: Common shares · 93,400 shares Expires 2018-02-14 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 31,134 on 02/15/2009, 31,133 on 02/15/2010, and 31,133 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC |
Michael Edward L.Executive Vice President
|
GrantCommon shares without par value | 23,000 | $55.56 | $1,277,880.00 |
DisclosureSEC source: 0001104659-08-011831 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,311 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC |
Tyree James LExecutive Vice President
|
GrantOption (right to buy) · Derivative | 127,500 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011832 · a4.xml · derivative · entry 7 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: Common shares · 127,500 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 42,500 on 02/15/2009, 42,500 on 02/15/2010, and 42,500 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC |
Tyree James LExecutive Vice President
|
GrantCommon shares without par value | 31,400 | $55.56 | $1,744,584.00 |
DisclosureSEC source: 0001104659-08-011832 · a4.xml · nonDerivative · entry 1 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,108 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:29 UTC |
FREYMAN THOMAS CExecutive Vice President
|
GrantOption (right to buy) · Derivative | 127,500 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · derivative · entry 9 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: common shares · 127,500 shares Expires 2018-02-14 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 42,500 on 2/15/09, 42,500 on 2/15/10 and 42,500 on 2/15/11. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:29 UTC |
FREYMAN THOMAS CExecutive Vice President
|
GrantCommon shares without par value | 31,400 | $55.56 | $1,744,584.00 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,755 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:29 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantOption (right to buy) · Derivative | 93,400 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011834 · a4.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,400 Underlying: common shares · 93,400 shares Expires 2018-02-14 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 31,134 on 2/15/09, 31,133 on 2/15/10 and 31,133 on 2/15/11. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:29 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantCommon shares without par value | 23,000 | $55.56 | $1,277,880.00 |
DisclosureSEC source: 0001104659-08-011834 · a4.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,800 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The awards have a 5 year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:30 UTC |
Bohuon OlivierSenior Vice President
|
GrantOption (right to buy) · Derivative | 97,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011835 · a4.xml · derivative · entry 2 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,700 Underlying: common shares · 97,700 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 32,567 on 2/15/2009, 32,567 on 2/15/10, and 32,566 on 2/15/11. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:30 UTC |
LINDER GREG WVice President
|
GrantOption (right to buy) · Derivative | 55,200 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011836 · a4.xml · derivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,200 Underlying: common shares · 55,200 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,400 on 02/15/2009, 18,400 on 02/15/2010, and 18,400 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:30 UTC |
LINDER GREG WVice President
|
GrantCommon shares without par value | 13,600 | $55.56 | $755,616.00 |
DisclosureSEC source: 0001104659-08-011836 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,132 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:30 UTC |
Landgraf John CSenior Vice President
|
GrantOption (right to buy) · Derivative | 78,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011837 · a4.xml · derivative · entry 7 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,700 Underlying: common shares · 78,700 shares Expires 2018-02-14 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,234 on 02/15/2009, 26,233 on 02/15/2010, and 26,233 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:30 UTC |
Landgraf John CSenior Vice President
|
GrantCommon shares without par value | 19,700 | $55.56 | $1,094,532.00 |
DisclosureSEC source: 0001104659-08-011837 · a4.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,907 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:31 UTC |
Hance Robert BSenior Vice President
|
GrantOption (right to buy) · Derivative | 78,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011839 · a4.xml · derivative · entry 6 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,700 Underlying: Common shares · 78,700 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,234 on 02/15/2009, 26,233 on 02/15/2010, and 26,233 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:31 UTC |
Hance Robert BSenior Vice President
|
GrantCommon shares without par value | 19,700 | $55.56 | $1,094,532.00 |
DisclosureSEC source: 0001104659-08-011839 · a4.xml · nonDerivative · entry 1 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,481 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:31 UTC |
Patton Donald V JRSenior Vice President
|
GrantOption (right to buy) · Derivative | 78,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011840 · a4.xml · derivative · entry 6 Patton Donald V JR · CIK 0001396490 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,700 Underlying: common shares · 78,700 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,234 on 02/15/2009, 26,233 on 02/15/2010, and 26,233 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:31 UTC |
Patton Donald V JRSenior Vice President
|
GrantCommon shares without par value | 19,700 | $55.56 | $1,094,532.00 |
DisclosureSEC source: 0001104659-08-011840 · a4.xml · nonDerivative · entry 1 Patton Donald V JR · CIK 0001396490 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,768 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:31 UTC |
Szela Mary TSenior Vice President
|
GrantOption (right to buy) · Derivative | 97,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011841 · a4.xml · derivative · entry 7 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,700 Underlying: common shares · 97,700 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,567 on 02/15/2009, 32,567 on 02/15/2010, and 32,566 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:31 UTC |
Szela Mary TSenior Vice President
|
GrantCommon shares without par value | 24,100 | $55.56 | $1,338,996.00 |
DisclosureSEC source: 0001104659-08-011841 · a4.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,674 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC |
Fussell Stephen RSenior Vice President
|
GrantOption (right to buy) · Derivative | 1,683 | $0.00 Strike: $56.34 | $0.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · derivative · entry 8 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,683 Underlying: common shares · 1,683 shares Expires 2010-02-10 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC |
Fussell Stephen RSenior Vice President
|
GrantOption (right to buy) · Derivative | 23,617 | $0.00 Strike: $56.34 | $0.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · derivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,617 Underlying: common shares · 23,617 shares Expires 2009-02-11 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC |
Fussell Stephen RSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 1,993 | $0.00 Strike: $43.25 | $0.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · derivative · entry 6 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731 Underlying: common shares · 1,993 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC |
Fussell Stephen RSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 28,485 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 28,485 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC |
Fussell Stephen RSenior Vice President
|
Tax withholdingCommon shares without par value | 25,300 | $56.34 | $1,425,402.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,321 Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC |
Fussell Stephen RSenior Vice President
|
Exercise / conversionCommon shares without par value | 1,993 | $43.25 | $86,197.25 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC |
Fussell Stephen RSenior Vice President
|
Exercise / conversionCommon shares without par value | 28,485 | $42.50 | $1,210,549.83 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC |
Michael Edward L.Executive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 31,045 | $0.00 Strike: $54.30 | $0.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · derivative · entry 9 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 31,045 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 400 | $56.17 | $22,468.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 8 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,311 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 1,500 | $56.16 | $84,240.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 7 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,711 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 745 | $56.15 | $41,831.75 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 6 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,211 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 2,700 | $56.13 | $151,551.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 5 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,956 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 2,200 | $56.12 | $123,464.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 4 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,656 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 3,000 | $56.11 | $168,330.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,856 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 20,500 | $56.10 | $1,150,050.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,856 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC |
Michael Edward L.Executive Vice President
|
Exercise / conversionCommon shares without par value | 31,045 | $54.30 | $1,685,743.50 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:48 UTC |
LINDER GREG WVice President
|
Exercise / conversionOption (right to buy) · Derivative | 1,775 | $0.00 Strike: $56.30 | $0.00 |
DisclosureSEC source: 0001104659-08-009506 · a4.xml · derivative · entry 15 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 1,775 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:48 UTC |
LINDER GREG WVice President
|
SaleCommon shares without par value | 1,775 | $56.40 | $100,110.00 |
DisclosureSEC source: 0001104659-08-009506 · a4.xml · nonDerivative · entry 11 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,532 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.